Allodynia (Pain From Nonpainful Stimulus)
Allodynia is most commonly caused by nerve (central or peripheral) pain sensitization, producing pain from light touch, clothing, or temperature. Pharmacologic treatment for neuropathic pain typically starts with amitriptyline, duloxetine, gabapentin, or pregabalin as initial options in non-specialist settings [1].
Common Underlying Causes
- Post–herpetic neuralgia or active shingles (often unilateral burning pain preceding or accompanied by a rash)
- Peripheral nerve injury or entrapment (e.g., radiculopathy, carpal tunnel, nerve compression)
- Diabetic peripheral neuropathy (often stocking–glove distribution) [2]
- Central neuropathic pain (e.g., after stroke, spinal cord injury) where allodynia can occur [3]
- Complex regional pain syndrome (CRPS) (disproportionate pain after an injury, with autonomic and skin/trophic changes)
- Migraine-associated cutaneous allodynia (hair/scalp tenderness during attacks)
Initial Clinical Assessment
- Timing and trigger identification should be performed (onset after injury, infection, vaccination, new medication, or neurologic event).
- Distribution mapping should be performed (dermatomal, stocking–glove, unilateral, localized, or generalized).
- Neurologic examination should be performed (sensation, reflexes, strength) to localize peripheral vs central involvement.
- Medication and substance review should be performed (especially recent dose changes that can worsen pain sensitivity).
- Screening for neuropathic patterns should be performed using bedside sensory testing (light touch, pinprick, temperature) to confirm allodynia.
Treatment Selection Algorithm
When allodynia is clinically consistent with neuropathic pain, first-line medication choices include:
- Tricyclic antidepressant: amitriptyline (or alternatives in practice) [1]
- SNRI: duloxetine [1]
- Gabapentinoids: gabapentin or pregabalin [1]
- Second-line escalation may include adding/switching among these classes based on response and tolerability [1]
Monotherapy vs Combination Therapy
- Initial monotherapy with one of the recommended first-line agents is standard for neuropathic pain initiation in non-specialist settings [1].
- Combination therapy is used when partial response occurs after adequate titration of a single agent. Drug combinations are considered when there is incomplete control of pain in neuropathic pain conditions [3].
Treatment Initiation Thresholds
- Medication initiation is appropriate when symptoms and examination findings are consistent with neuropathic pain features, including allodynia, after excluding emergent causes.
- Medication selection should account for comorbid depression/anxiety (supporting TCA or SNRI selection) and neurologic risk profile (e.g., fall risk with TCAs in older adults).
- For painful diabetic neuropathy specifically, pregabalin is recommended as effective when clinically appropriate per evidence-based guideline level A in painful diabetic neuropathy [2].
Common Pitfalls to Avoid
- Mislabeling allodynia as purely “skin” tenderness without neurologic localization, despite the common neuropathic mechanism.
- Delayed evaluation for shingles when unilateral dermatomal pain precedes rash, since early antiviral treatment is time-sensitive.
- Insufficient titration and reassessment, which is a frequent reason for apparent treatment failure in neuropathic pain management [1].
Red Flags Requiring Urgent/Emergent Evaluation
- New weakness, gait instability, bowel/bladder dysfunction, or rapidly progressive neurologic deficits
- Fever with severe pain, immunocompromise, or suspected spinal infection
- Suspected acute stroke symptoms
- Active shingles with severe pain plus eye involvement (ophthalmic distribution)
Expected Outcomes and Goals
- Goals should be defined as reduction in neuropathic pain intensity and improved function, with follow-up after dose titration and tolerability checks.
- A structured first-line approach using amitriptyline, duloxetine, gabapentin, or pregabalin is recommended for neuropathic pain in non-specialist settings [1].